vimarsana.com

Page 24 - Advanced Accelerator Applications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Radiopharm Theranostics Ltd s diversified portfolio of cancer treatments sees it make promising debut: Independent Investment Research

The broker has assigned RAD a value of $0.86 per share – $0.76 per share on a fully diluted basis – which accounts for the strongest assets.

¹⁷⁷Lu-Dotatate Provides Clinically Relevant Improvement in Midgut Neuroendocrine Tumors

Adding ¹⁷⁷Lu-Dotatate to long-acting octreotide led to a “clinically relevant,” but not statistically significant, improvement in overall survival.

¹⁷⁷Lu-Dotatate Provides Clinically Relevant Improvement in Midgut Neuroendocrine Tumors

Adding ¹⁷⁷Lu-Dotatate to long-acting octreotide led to a “clinically relevant,” but not statistically significant, improvement in overall survival.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.